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論文の要旨 
Abstract of thesis 
 
Introduction: Insomnia is one of the most common sleep problems with an estimated prevalence 
of 10-15% in the general population and 30-60% in the older population. The adenosine A2A 
receptor (A2AR) agonist CGS 21680 induces sleep when infused into the brain of rodents. However, 
it is commonly believed that administration of an A2AR agonist has limited clinical potential 
for treating sleep disorders, because of its cardiovascular side effects, including hypotension 
and tachycardia. Moreover, all currently existing A2AR agonists are not suitable for treating 
the central nervous system due to the lack of brain permeability, as it is widely accepted 
that the basic adenosine scaffold must be maintained in an A2AR agonist. Selective physiologic 
A2AR responses may, however, be evoked by a positive allosteric modulator, because its action, 
in contrast an orthosteric ligand, is limited to when and where the endogenous ligands are 
released. Allosteric modulation may be an alternative strategy for the treatment of insomnia, 
because the elevation of extracellular adenosine levels in the brain is positively associated 
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 with sleep. The main objective of this study was to prove this hypothesis.  
Materials and methods: The author established A2AR-expressing Chinese hamster ovary cells to 
measure cAMP produced upon A2AR activation by using a fluorescence resonance energy transfer 
immunoassay and subsequently, screened 1194 small-molecule compounds for allosteric effects 
at A2AR in the cell-culture bioassay. The author determined sleep-inducing effects of the 
compound measured by using SLEEPSIGN, a sleep recording systems, effects of compound on blood 
pressure measured by using an electrosphygmomanometer, and heart rhythm monitored by using an 
electrocardiography, and body temperature by using body core temperature sensors, iButton.  
 
Results: The author identified a positive allosteric modulator for A2AR (A2AR PAM-1) in cell-
culture system. When the author examined the sleep inducing activity of A2AR PAM-1 by monitoring 
the electroencephalogram, the author found that the intraperitoneal (i.p.) administration of 
A2AR PAM-1 dose dependently (30-75 mg/kg) increased the total amount of slow wave sleep (SWS). 
The SWS-inducing effect of A2AR PAM-1 was suppressed by A2AR antagonist ZM 241385 (15 mg/kg, 
i.p.) and abolished in A2AR knockout mice. Moreover, direct infusion of A2AR PAM-1 (200 nmol/ml) 
into the brain of mice during the night strongly induced SWS. In contrast to A2AR agonist CGS 
21680, blood pressure measured by using an electrosphygmomanometer, heart rhythm monitored by 
using electrocardiography, and body temperature measured by using temperature sensors iButton 
was not affected after i.p. administration of A2AR PAM-1. 
 
Discussion: The author suggestd that enhancing A2AR signaling by intraperitoneal administration 
of A2AR PAM-1 induces SWS without cardiovascular effects in mice. Therefore, A2AR-modulating 
compounds may provide safe options for the treatment of insomnia and poor- quality sleep. The 
observation in animals that adenosine levels are elevated during prolonged wakefulness may 
explain why an allosteric modulator could effectively enhance the sleep-inducing effect of 
endogenous adenosine in the brain. On the other hand, adenosine was absent or its concentration 
was too low in the cardiovascular system under physiologic conditions to affect blood pressure 
and heart function after administration of an allosteric modulator of A2AR. Small lipophilic 
monocarboxylates like A2AR PAM-1 likely pass through the blood-brain-barrier by passive 
diffusion or via a monocarboxylate transport system. Therefore, allosteric modulation of A2ARs 
has the potential to cause pharmacologic effects in the central nervous system after systemic 
administration, resulting in good quality sleep. However, the author’s study did not elucidate 
where and how the A2AR PAM-1 binds to the receptor and exert its allosteric effects. Moreover, 
 the author’s work did not address the possible sleep-inducing effects of the A2AR PAM-1 in 
the human use. Many obstacles remain to be overcome in generating a novel drug for the treatment 
of insomnia in humans.  
 
Conclusions: Small molecules like A2AR PAM-1 may help people with sleep problems to fall asleep. 
 
 
審査の要旨 
 Abstract of assessment result 
 
【批評 Review】 
The findings of this study indicate that enhancing A2AR signaling promotes slow-wave sleep 
without affecting cardiovascular functions and body temperature. Therefore, small molecules 
that allosterically modulate A2ARs could help people with sleep problems to fall asleep and 
thus also be a potential treatment for psychiatric disorders. The strong points of this work 
could be summarized as like below: This study elucidated at the first time that positive 
allosteric modulation of adenosine A2AR promotes slow-wave sleep in a dose-dependent manner in 
mice. Inducing slow-wave sleep via adenosine A2AR positive allosteric modulator does not cause 
hypotension or affect blood pressure and heart rate/rhythm. On the other hand, the weak points 
of this work could be counted as below: This study did not investigate how and where the A2AR 
PAM-1 binds at the receptor to exert its allosteric effect. Therefore, an important next step 
will be to examine the allosteric interactions of A2AR PAM-1 and the receptor using binding 
assays and crystal structure analysis.  
 
【最終試験の結果 Result】 
The final examination committee conducted a meeting as a final examination on 17 December, 
2018. The applicant provided an overview of dissertation, addressed questions and comments 
raised during Q&A session. All of the committee members reached a final decision that the 
applicant has passed the final examination. 
 
【結論 Conclusion】 
Therefore, the final examination committee approved that the applicant is qualified to be 
awarded a Doctor of Philosophy in Human Biology. 
